Astellas teams up with UK biotech Mogrify on hearing loss project
pharmaphorum
JULY 5, 2022
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. SNHL is the most common form of hearing loss, account for more than 90% of cases and affecting millions of people worldwide.
Let's personalize your content